Emma C. Kozurek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Emma C. Kozurek has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah
College of Pharmacy, Chungnam National University, Daejeon 34134, Republic of Korea
1 shared publication - Donghee Lee
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, United SA
1 shared publication Erin B. Dickerson
Animal Cancer Care and Research Program, University of Minnesota, St Paul, USA
1 shared publicationEthan J. Wong
Animal Cancer Care and Research Program, University of Minnesota, St Paul, USA
1 shared publicationHai Dang Nguyen
Masonic Cancer Center, University of Minnesota, Minneapolis, USA
1 shared publication- Jong Hyuk Kim
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, United SA; UF Health Cancer Institute, University of Florida, Gainesville, Florida, USA; Artificial Intelligence Academic Initiative (AI(2)) Center, University of Florida, Gainesville, Florida, USA; Intelligent Critical Care Center (IC(3)), University of Florida, Gainesville, Florida, USA
1 shared publication
Latest Publications
- Open Access
- 21 December 2024
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 32 (2) , 254-267
PIK3CA mutation fortifies molecular determinants for immune signaling in vascular cancers
Angiosarcomas are a group of vascular cancers that form malignant blood vessels. These malignancies are seemingly inflamed primarily due to their pathognomonic nature, which consists of irregular endothelium and tortuous blood channels. PIK3CA mutations are oncogenic and disrupt the PI3K pathway. In this study, we aimed to define the molecular and functional consequences of oncogenic PIK3CA mutations in angiosarcoma. We first generated two isogenic hemangiosarcoma cell lines harboring the H1047R hotspot mutations in PIK3CA gene using CRISPR/Cas9. We found PIK3CA-mutant cells established distinct molecular signatures in global gene expression and chromatin accessibility, which were associated with enrichment of immune cytokine signaling, including IL-6, IL-8, and MCP-1. These molecular processes were disrupted by the PI3K-α specific inhibitor, alpelisib. We also observed that the molecular distinctions in PIK3CA-mutant cells were linked to metabolic reprogramming in glycolytic activity and mitochondrial respiration. Our multi-omics analysis revealed that activating PIK3CA mutations regulate molecular machinery that contributes to phenotypic alterations and resistance to alpelisib. Furthermore, we identified potential therapeutic vulnerabilities of PIK3CA mutations in response to PI3K-α inhibition mediated by MAPK signaling. In summary, we demonstrate that PIK3CA mutations perpetuate PI3K activation and reinforce immune enrichment to promote drug resistance in vascular cancers.
- 21 December 2024
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 32 (2) , 254-267
Open AccessPIK3CA mutation fortifies molecular determinants for immune signaling in vascular cancers
Angiosarcomas are a group of vascular cancers that form malignant blood vessels. These malignancies are seemingly inflamed primarily due to their pathognomonic nature, which consists of irregular endothelium and tortuous blood channels. PIK3CA mutations are oncogenic and disrupt the PI3K pathway. In this study, we aimed to define the molecular and functional consequences of oncogenic PIK3CA mutations in angiosarcoma. We first generated two isogenic hemangiosarcoma cell lines harboring the H1047R hotspot mutations in PIK3CA gene using CRISPR/Cas9. We found PIK3CA-mutant cells established distinct molecular signatures in global gene expression and chromatin accessibility, which were associated with enrichment of immune cytokine signaling, including IL-6, IL-8, and MCP-1. These molecular processes were disrupted by the PI3K-α specific inhibitor, alpelisib. We also observed that the molecular distinctions in PIK3CA-mutant cells were linked to metabolic reprogramming in glycolytic activity and mitochondrial respiration. Our multi-omics analysis revealed that activating PIK3CA mutations regulate molecular machinery that contributes to phenotypic alterations and resistance to alpelisib. Furthermore, we identified potential therapeutic vulnerabilities of PIK3CA mutations in response to PI3K-α inhibition mediated by MAPK signaling. In summary, we demonstrate that PIK3CA mutations perpetuate PI3K activation and reinforce immune enrichment to promote drug resistance in vascular cancers.